Podcast appearances and mentions of David S Hong

Dr. David S. Hong of the University of Texas MD Anderson Cancer Center in Houston, Texas joins us on the podcast to discuss investigational cancer therapeutics.

Dr. David S. Hong of the University of Texas MD Anderson Cancer Center in Houston, Texas joins us on the podcast to discuss investigational cancer therapeutics.

Dr. David S. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong received a bachelor’s degree in biology from Yale University and a medical degree from Albert Einstein College of Medicine. He then completed an internship and residency at Thomas Jefferson University Hospital and a medical oncology fellowship at MD Anderson, during which time he was appointed chief medical oncology fellow. In 2005, he joined MD Anderson’s faculty. Dr. Hong is the recipient of the 2004 Young Investigator Award from the American Society of Clinical Oncology, the Jesse H. Jones Fellowship in Cancer Education, MD Anderson’s Best Boss Award, the Irwin H. Krakoff Award for Excellence in Clinical Research, the Gerald P. Bodey Award for Excellence in Education and a research training fellowship from Howard Hughes Medical Institute. He has published more than 270 articles in prestigious journals. John Marchica is a veteran health care strategist and COO of Darwin Research Group, a health care market intelligence firm specializing in health care delivery systems. He’s a two-time health care entrepreneur, and his first company, FaxWatch, was listed twice on the Inc. 500 list of fastest-growing American companies. John is the author of The Accountable Organization and has advised senior management on strategy and organizational change for more than a decade. John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is a faculty associate in the W.P. Carey School of Business and the College of Health Solutions at Arizona State University and is an active member of the American College of Healthcare Executives. About Darwin Research Group   Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

In today’s episode, John returns to his conversation with renowned cancer researcher Dr. David S. Hong. Dr. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong has published more than 270 papers in leading academic journals. Topics include: Go/No-go decisions in clinical trials. Interchangeability of oncology drugs and biosimilars. Rising drug prices and declining trust in pharmaceutical companies. Health care delivery in the United States. Speaker Bios Dr. David S. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong received a bachelor’s degree in biology from Yale University and a medical degree from Albert Einstein College of Medicine. He then completed an internship and residency at Thomas Jefferson University Hospital and a medical oncology fellowship at MD Anderson, during which time he was appointed chief medical oncology fellow. In 2005, he joined MD Anderson’s faculty. Dr. Hong is the recipient of the 2004 Young Investigator Award from the American Society of Clinical Oncology, the Jesse H. Jones Fellowship in Cancer Education, MD Anderson’s Best Boss Award, the Irwin H. Krakoff Award for Excellence in Clinical Research, the Gerald P. Bodey Award for Excellence in Education and a research training fellowship from Howard Hughes Medical Institute. He has published more than 270 articles in prestigious journals. John Marchica is a veteran health care strategist and CEO of Darwin Research Group, a health care market intelligence firm specializing in health care delivery systems. He’s a two-time health care entrepreneur, and his first company, FaxWatch, was listed twice on the Inc. 500 list of fastest growing American companies. John is the author of The Accountable Organization and has advised senior management on strategy and organizational change for more than a decade. John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is a faculty associate in the W.P. Carey School of Business and the College of Health Solutions at Arizona State University, and is an active member of the American College of Healthcare Executives. About Darwin Research Group Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

In today’s episode, John has a fascinating conversation with renowned cancer researcher Dr. David S. Hong. Dr. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong has published more than 270 papers in leading academic journals. Topics include: The rise of immunotherapy and the Golden Age of cancer treatment. The role of clinical pathways and personalized medicine in improving patient care. Industry-researcher collaborations and investments in clinical trials. How physicians balance research with providing clinical care. Speaker Bios Dr. David S. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong received a bachelor’s degree in biology from Yale University and a medical degree from Albert Einstein College of Medicine. He then completed an internship and residency at Thomas Jefferson University Hospital and a medical oncology fellowship at MD Anderson, during which time he was appointed chief medical oncology fellow. In 2005, he joined MD Anderson’s faculty. Dr. Hong is the recipient of the 2004 Young Investigator Award from the American Society of Clinical Oncology, the Jesse H. Jones Fellowship in Cancer Education, MD Anderson’s Best Boss Award, the Irwin H. Krakoff Award for Excellence in Clinical Research, the Gerald P. Bodey Award for Excellence in Education and a research training fellowship from Howard Hughes Medical Institute. He has published more than 270 articles in prestigious journals. John Marchica is a veteran health care strategist and CEO of Darwin Research Group, a health care market intelligence firm specializing in health care delivery systems. He’s a two-time health care entrepreneur, and his first company, FaxWatch, was listed twice on the Inc. 500 list of fastest growing American companies. John is the author of The Accountable Organization and has advised senior management on strategy and organizational change for more than a decade. John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is a faculty associate in the W.P. Carey School of Business and the College of Health Solutions at Arizona State University, and is an active member of the American College of Healthcare Executives. About Darwin Research Group Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

JAACAP March 2016: Contributing Editor Dr. David S. Hong interviews Dr. Kristina R. Olson on understanding the development and stability of gender identity for clinicians working with transgender youth.

JAACAP March 2016: Contributing Editor Dr. David S. Hong interviews Dr. Kristina R. Olson on understanding the development and stability of gender identity for clinicians working with transgender youth.

JAACAP September 2015: Contributing Editor Dr. David S. Hong interviews Dr. Kenneth J. Ruggiero on possible causes and implications of sustained use of Web-based interventions.

JAACAP September 2015: Contributing Editor Dr. David S. Hong interviews Dr. Kenneth J. Ruggiero on possible causes and implications of sustained use of Web-based interventions.

JAACAP March 2014: Contributing Editor Dr. David S. Hong interviews Dr. John Piacentini on combined behavioral therapy and selective serotonin reuptake inhibitor medication treatment in the Child/Adolescent Anxiety Multimodal Study (CAMS).

JAACAP March 2014: Contributing Editor Dr. David S. Hong interviews Dr. John Piacentini on combined behavioral therapy and selective serotonin reuptake inhibitor medication treatment in the Child/Adolescent Anxiety Multimodal Study (CAMS).